IGF-1 LR3

IGF-1 LR3 is a modified insulin-like growth factor analog studied for extended bioavailability, anabolic signaling, and body-composition research.

Profile · 01

Overview

IGF-1 LR3 is a modified analog of human insulin-like growth factor 1 that includes an N-terminal extension and a substitution that reduce binding to IGF-binding proteins. It is not FDA-approved for human therapeutic use and remains a research-only compound.

The source emphasizes that extended half-life and stronger systemic exposure come with a meaningful tradeoff: insulin-like blood-glucose effects can make hypoglycemia the dominant practical risk.

At a Glance

Goal
Support anabolic and metabolic signaling through sustained IGF-1 receptor activation
Categories
AnabolicMetabolicBody CompositionRecoveryResearch
Synergistic
HGH 191AA · CJC-1295 NO DAC + Ipamorelin · BPC-157 · TB-500
Profile · 02

Protocol

Suggested daily titration approach starting low and increasing every two weeks to assess blood-glucose tolerance.

Reconstitute
Add 3.0 mL bacteriostatic water to a 1 mg vial for about 333 mcg/mL concentration
Typical daily range
20-50 mcg once daily
Start
20 mcg daily for Weeks 1-2
Target
40-50 mcg daily by Weeks 3-8
Frequency
Once per day (subcutaneous)
Cycle Length
8 weeks standard; longer cycles may show diminishing returns
Timing
Morning or post-workout with food to reduce glucose risk
Route
Subcutaneous
Cycle
8 weeks on, 4-8 weeks off

Inject once daily subcutaneously with food or shortly after eating. The insulin-like effect on blood glucose is the main safety concern, so the source strongly emphasizes conservative dosing and access to a fast-acting carbohydrate source if symptoms occur.

Dose progression

Weeks 1-2
20 mcg (0.02 mg) · 6 units (0.06 mL)
Weeks 3-4
40 mcg (0.04 mg) · 12 units (0.12 mL)
Weeks 5-8
50 mcg (0.05 mg) · 15 units (0.15 mL)

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Science · 01

How IGF-1 LR3 works.

IGF-1 LR3 has reduced affinity for IGF-binding proteins, which extends half-life from minutes toward hours and increases systemic exposure relative to native IGF-1. It supports anabolic and metabolic signaling through the IGF-1 receptor.

That same biology also explains its main practical downside: insulin-like effects on blood glucose can become clinically relevant even when the dose seems small. The source repeatedly emphasizes conservative dosing and glucose awareness.

Science · 02

Effects

Observations from clinical or preclinical literature.

Supports sustained anabolic signaling and protein-synthesis discussion in research settings
Has longer effective exposure than native IGF-1 because binding-protein interaction is reduced
May support body-composition and recovery goals through IGF-1-receptor pathways
Hypoglycemia is the main safety concern and can present with shakiness, sweating, dizziness, or confusion
Mild injection-site irritation may occur
Long-term human safety is not established because this compound has no therapeutic approval base
Science · 03

Caution

Avoid in active cancer or significant cancer history because IGF-1 signaling is growth-promoting
Avoid in diabetes or hypoglycemia-prone states because blood-glucose effects are central to the risk profile
Not recommended during pregnancy or breastfeeding because safety data is insufficient
Do not treat this like a casual body-composition peptide; glucose monitoring awareness is essential

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Lifestyle · 01

CoFactors

Protein intake
Supports anabolic adaptation and recovery during IGF-signaling-focused protocols.
Zinc
Relevant to IGF-related signaling and tissue recovery.
Magnesium
Supports metabolic and recovery processes.
Vitamin D
Relevant to musculoskeletal and endocrine health.
Chromium
Sometimes discussed for glucose-support context, given the insulin-like risk profile.
Lifestyle · 02

Life Factors

Complementary strategies for best outcomes.

Maintain regular meal timing and avoid running this protocol in a poorly fed state
Use resistance training if the goal is anabolic adaptation rather than scale weight alone
Prioritize sleep and recovery because the protocol is not a substitute for foundational recovery inputs
Consider periodic blood-glucose checks if symptoms suggest hypoglycemia
Lifestyle · 03

Metrics

Day-to-day metrics worth tracking through the protocol.

  1. Blood glucose and hypoglycemic symptoms - the single most important safety metric here
  2. Body composition - track lean-mass and fat-mass trends
  3. Energy, shakiness, sweating, or dizziness - log any episodes that suggest poor dose tolerance
  4. Injection-site reactions - note redness, swelling, or discomfort
Lifestyle · 04

Labs

Baseline and periodic bloodwork to monitor systemic health during the protocol.

Fasting glucose and HbA1c
Core safety markers given the insulin-like effect profile.
Fasting insulin
Useful for insulin-sensitivity context.
IGF-1
Tracks broader growth-factor exposure during the cycle.
CBC (Complete Blood Count)
General monitoring and baseline screening.
CMP (Comprehensive Metabolic Panel)
Assess broader systemic function during the protocol.
Lipid panel
Useful for metabolic-health context when body-composition goals are involved.
Calculators · 01

Supplies Calculator

Estimates assume the schedule defined for this peptide.

Length
Vial size
Bac. water
Syringe
Vials
0 × 1 mg each…
Syringes
0
Bac. water
0 mL
Swabs
02 per syringe
Calculators · 02

Dose Calculator

Dose Calculator

Vial
Bac. water
Syringe
Dose
Concentration
0mcg/mL
Volume per dose
0mL
…
Practice · 01

Preparation

Careful technique preserves potency. Solution should be clear — do not shake.

  1. Allow vial to reach room temperature for 15–20 minutes before reconstitution.
  2. Draw the chosen bacteriostatic water volume with a sterile syringe.
  3. Inject slowly down vial wall; avoid foaming.
  4. Gently swirl/roll until dissolved (do not shake).
  5. Label with reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
  6. Use within 30 days; discard any unused solution after 30 days.
Practice · 02

Technique

General subcutaneous guidance from clinical best-practice resources.

Clean the vial stopper and injection site with alcohol and allow them to dry fully
Pinch a skinfold and insert the needle at 45-90 degrees into subcutaneous tissue
Do not aspirate for subcutaneous injections; inject slowly and steadily
Rotate sites across the abdomen, thighs, and upper arms to reduce local irritation
Discard used syringes immediately in a sharps container

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Practice · 03

Storage

Lyophilized
Store at room temp in dry, dark conditions; minimize moisture exposure.
Reconstituted
Refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles. Discard reconstituted vials after 30 days.

Notes

Allow vials to reach room temperature before opening to reduce condensation uptake.
Reference · 01

Notes

Use a new sterile insulin syringe for each injection and dispose of it safely
Always take this protocol with or around food rather than in a fasted state
Keep a fast-acting carbohydrate source available if hypoglycemic symptoms occur
The source strongly favors staying under the 50-60 mcg per day zone
PepTribe is an educational platform. This information is for research and learning purposes only and is not medical advice.
Reference · 02

References

  1. MDPI Biomolecules
    IGF-1 structure, function, and monitoring overview.
    https://www.mdpi.com/2218-273X/11/2/217
  2. Dopinglinkki
    IGF-1 and IGF-1 LR3 pharmacology and anti-doping overview.
    https://dopinglinkki.fi/en/info-bank/doping-substances/igf-1
  3. Frontiers in Bioengineering & Biotechnology
    IGF-1 LR3 discussion in tissue-engineering and bioavailability context.
    https://www.frontiersin.org/articles/10.3389/fbioe.2020.00167/full
  4. PubMed
    Detection and characterization of IGF-1 LR3 in biological samples.
    https://pubmed.ncbi.nlm.nih.gov/23495176/
  5. CDC
    Subcutaneous injection route guidance.
    https://www.cdc.gov/vaccines/hcp/admin/downloads/YCTS-VaxAdmin-Subcut-injection.pdf
On this page